E22W42

**E22W42** is an investigational therapeutic vaccine for Alzheimer's disease consisting of dendritic cells (DC) loaded with a modified amyloid-beta (Aβ) peptide antigen featuring mutations at positions E22 and W42. Developed by researchers at the University of South Florida, including Dr. Chuanhai Cao, it specifically targets toxic oligomeric forms of Aβ to induce a strong antibody response while minimizing autoimmune reactions and neuroinflammation, addressing limitations of prior vaccines like AN1792. Preclinical studies in transgenic Alzheimer's mouse models demonstrated reduced memory impairment, elevated anti-Aβ antibodies in brain and blood, and no significant increase in inflammatory cytokines, suggesting potential safety and efficacy in halting disease progression.

Other names

E22W42 DCE-22W42 DCE 22W42 DC